Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2013 3
2015 1
2017 1
2018 2
2022 2
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease.
Nissen SE, Wolski K, Cho L, Nicholls SJ, Kastelein J, Leitersdorf E, Landmesser U, Blaha M, Lincoff AM, Morishita R, Tsimikas S, Liu J, Manning B, Kozlovski P, Lesogor A, Thuren T, Shibasaki T, Matei F, Silveira FS, Meunch A, Bada A, Vijan V, Bruun NE, Nordestgaard BG; Lp(a)HERITAGE Investigators. Nissen SE, et al. Among authors: lesogor a. Open Heart. 2022 Oct;9(2):e002060. doi: 10.1136/openhrt-2022-002060. Open Heart. 2022. PMID: 36252994 Free PMC article.
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S. Willeit P, et al. Among authors: lesogor a. Lancet. 2018 Oct 13;392(10155):1311-1320. doi: 10.1016/S0140-6736(18)31652-0. Epub 2018 Oct 4. Lancet. 2018. PMID: 30293769 Free article.
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
Ray KK, Troquay RPT, Visseren FLJ, Leiter LA, Scott Wright R, Vikarunnessa S, Talloczy Z, Zang X, Maheux P, Lesogor A, Landmesser U. Ray KK, et al. Among authors: lesogor a. Lancet Diabetes Endocrinol. 2023 Feb;11(2):109-119. doi: 10.1016/S2213-8587(22)00353-9. Epub 2023 Jan 5. Lancet Diabetes Endocrinol. 2023. PMID: 36620965 Free article. Clinical Trial.
Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects.
Karwatowska-Prokopczuk E, Lesogor A, Yan JH, Hurh E, Hoenlinger A, Margolskee A, Xia S, Tsimikas S. Karwatowska-Prokopczuk E, et al. Among authors: lesogor a. J Clin Lipidol. 2023 Jan-Feb;17(1):181-188. doi: 10.1016/j.jacl.2022.12.001. Epub 2022 Dec 8. J Clin Lipidol. 2023. PMID: 36529659 Clinical Trial.
Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP; ASTRONAUT Investigators and Coordinators. Gheorghiade M, et al. Among authors: lesogor a. JAMA. 2013 Mar 20;309(11):1125-35. doi: 10.1001/jama.2013.1954. JAMA. 2013. PMID: 23478743 Clinical Trial.
Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients.
White WB, Bresalier R, Kaplan AP, Palmer BF, Riddell RH, Lesogor A, Chang W, Keefe DL. White WB, et al. Among authors: lesogor a. J Clin Hypertens (Greenwich). 2011 Jul;13(7):506-16. doi: 10.1111/j.1751-7176.2011.00438.x. Epub 2011 Mar 18. J Clin Hypertens (Greenwich). 2011. PMID: 21762364 Free PMC article.
Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.
Greene SJ, Maggioni AP, Fonarow GC, Solomon SD, Böhm M, Kandra A, Prescott MF, Reimund B, Hua TA, Lesogor A, Zannad F, Gheorghiade M; ASTRONAUT Investigators and Coordinators. Greene SJ, et al. Among authors: lesogor a. Eur J Heart Fail. 2015 Jan;17(1):98-108. doi: 10.1002/ejhf.201. Eur J Heart Fail. 2015. PMID: 25597870 Free article.
Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies.
Pivonello R, Muscogiuri G, Holder G, Paul M, Sarp S, Lesogor A, Jordaan P, Eisinger J, Colao A. Pivonello R, et al. Among authors: lesogor a. Endocrine. 2018 Apr;60(1):65-72. doi: 10.1007/s12020-017-1448-5. Epub 2017 Nov 7. Endocrine. 2018. PMID: 29116540 Free PMC article. Clinical Trial.
Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study.
Lesogor A, Cohn JN, Latini R, Tognoni G, Krum H, Massie B, Zalewski A, Kandra A, Hua TA, Gimpelewicz C. Lesogor A, et al. Eur J Heart Fail. 2013 Nov;15(11):1236-44. doi: 10.1093/eurjhf/hft089. Epub 2013 Jun 19. Eur J Heart Fail. 2013. PMID: 23787721 Free article. Clinical Trial.
11 results